Iterum Therapeutics Public Limited Company, a clinical-stage pharmaceutical entity headquartered in Chicago, United States, has been actively engaged in the development and marketing of therapies aimed at addressing unmet medical needs. The company’s primary focus is on creating anti-infectives designed to combat multi-drug resistant pathogens, a critical area in contemporary healthcare. Serving a global clientele, Iterum Therapeutics provides its innovative solutions to physicians and patients worldwide.

As of October 19, 2025, Iterum Therapeutics’ stock was trading at a close price of $0.75 on the Nasdaq stock exchange. This figure represents a significant decline from the company’s 52-week high of $3.02, recorded on December 8, 2024. Conversely, the stock reached its 52-week low of $0.611 on September 2, 2025. The market capitalization of Iterum Therapeutics stands at approximately $30,110,000 USD, reflecting the current valuation of the company in the market.

The financial metrics of Iterum Therapeutics indicate a Price Earnings (P/E) ratio of -0.85. This negative P/E ratio suggests that the company is currently not generating profits, which is not uncommon for clinical-stage pharmaceutical companies that are heavily invested in research and development.

Iterum Therapeutics was established as a public company following its Initial Public Offering (IPO) on May 25, 2018. Since then, the company has been listed on the Nasdaq, providing investors with the opportunity to participate in its growth and development. For more detailed information about Iterum Therapeutics, stakeholders and interested parties are encouraged to visit the company’s official website at www.iterumtx.com .

In summary, Iterum Therapeutics continues to focus on its mission to develop and market therapies that address critical medical needs, particularly in the realm of anti-infectives for multi-drug resistant pathogens. Despite the challenges reflected in its current financial metrics, the company remains committed to its strategic objectives and serves a vital role in the global healthcare landscape.